Taken together, the in vivo evidence suggests that CREBZF is required for the beneficial effects of bromocriptine on anti‐inflammatory phenotype and improved insulin sensitivity in mice, and pharmacological inhibition of CREBZF may have potential therapeutic effects on metabolic disorders. This evidence concerns the gene INS and metabolic disease.